Domestic pharmaceutical companies have broken the Sevikar patent, giving generics positive signs
Domestic pharmaceutical companies have succeeded in breaking the Sevikar patent.
According to the Intellectual Property Tribunal, 3 pharmaceutical companies, such as Korea United Pharm, JW Pharmaceutical and JRP, have completely nullified the patent of the Daiichi-Sankyo’s hypertension complex, ...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
